SEC Form 4 · accession 0001012975-18-000335
Altimmune, Inc. · ALT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mitchel Sayare
Director
Period of report
Apr 5, 2018
Accepted (ET)
Apr 6, 2018 · 8:27 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001326190
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (option to buy)F1 | $0.95 | Apr 5, 2018 | A | 35,000 | A | — | Apr 5, 2028 | Common Stock, par value $0.0001 | 35,000 | 35,000 | D |
Explanation of responses
- F1Fifty percent of the option will become vested and exercisable on June 30, 2018 and the remaining 50% of the option will vest and become exercisable on December 31, 2018.